Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Author Correction: Genomic characterization of metastatic breast cancers.
Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, Soria JC, Dien AT, Adnani Y, Kamal M, Garnier S, Meurice G, Jimenez M, Dogan S, Verret B, Chaffanet M, Bachelot T, Campone M, Lefeuvre C, Bonnefoi H, Dalenc F, Jacquet A, De Filippo MR, Babbar N, Birnbaum D, Filleron T, Le Tourneau C, André F. Bertucci F, et al. Among authors: patsouris a. Nature. 2019 Aug;572(7767):E7. doi: 10.1038/s41586-019-1380-3. Nature. 2019. PMID: 31308536
Vinflunine for the treatment of breast cancer.
Gourmelon C, Bourien H, Augereau P, Patsouris A, Frenel JS, Campone M. Gourmelon C, et al. Among authors: patsouris a. Expert Opin Pharmacother. 2016 Sep;17(13):1817-23. doi: 10.1080/14656566.2016.1217991. Epub 2016 Aug 10. Expert Opin Pharmacother. 2016. PMID: 27484180 Review.
Olaparib for the treatment of breast cancer.
Robert M, Frenel JS, Gourmelon C, Patsouris A, Augereau P, Campone M. Robert M, et al. Among authors: patsouris a. Expert Opin Investig Drugs. 2017 Jun;26(6):751-759. doi: 10.1080/13543784.2017.1318847. Epub 2017 Apr 21. Expert Opin Investig Drugs. 2017. PMID: 28395540 Review.
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.
Augereau P, Patsouris A, Bourbouloux E, Gourmelon C, Abadie Lacourtoisie S, Berton Rigaud D, Soulié P, Frenel JS, Campone M. Augereau P, et al. Among authors: patsouris a. Ther Adv Med Oncol. 2017 May;9(5):335-346. doi: 10.1177/1758834017693195. Epub 2017 Mar 14. Ther Adv Med Oncol. 2017. PMID: 28529550 Free PMC article. Review.
Efficacy of buparlisib in treating breast cancer.
Robert M, Frenel JS, Bourbouloux E, Berton Rigaud D, Patsouris A, Augereau P, Gourmelon C, Campone M. Robert M, et al. Among authors: patsouris a. Expert Opin Pharmacother. 2017 Dec;18(18):2007-2016. doi: 10.1080/14656566.2017.1410139. Epub 2017 Dec 1. Expert Opin Pharmacother. 2017. PMID: 29169282
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.
Gobbini E, Ezzalfani M, Dieras V, Bachelot T, Brain E, Debled M, Jacot W, Mouret-Reynier MA, Goncalves A, Dalenc F, Patsouris A, Ferrero JM, Levy C, Lorgis V, Vanlemmens L, Lefeuvre-Plesse C, Mathoulin-Pelissier S, Petit T, Uwer L, Jouannaud C, Leheurteur M, Lacroix-Triki M, Cleaud AL, Robain M, Courtinard C, Cailliot C, Perol D, Delaloge S. Gobbini E, et al. Among authors: patsouris a. Eur J Cancer. 2018 Jun;96:17-24. doi: 10.1016/j.ejca.2018.03.015. Epub 2018 Apr 13. Eur J Cancer. 2018. PMID: 29660596
An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.
Robert M, Frenel JS, Bourbouloux E, Rigaud DB, Patsouris A, Augereau P, Gourmelon C, Campone M. Robert M, et al. Among authors: patsouris a. Drugs. 2018 Sep;78(13):1353-1362. doi: 10.1007/s40265-018-0972-9. Drugs. 2018. PMID: 30143968 Review.
Emerging PARP inhibitors for treating breast cancer.
Robert M, Patsouris A, Frenel JS, Gourmelon C, Augereau P, Campone M. Robert M, et al. Among authors: patsouris a. Expert Opin Emerg Drugs. 2018 Sep;23(3):211-221. doi: 10.1080/14728214.2018.1527900. Epub 2018 Sep 29. Expert Opin Emerg Drugs. 2018. PMID: 30251552 Review.
54 results